Introduction {#s1}
============

Parkinson's disease (PD) is the most prevalent neurodegenerative movement disorder. The defining pathological features of PD are the loss of dopaminergic neurons in the substantia nigra (SN) and the intraneuronal presence of α-synuclein inclusions (Lewy bodies and Lewy neurites) ([@bib19]). Although the pathogenic mechanisms underlying PD are not understood in detail, mitochondrial dysfunction and dysregulation of calcium homeostasis are thought to play a crucial role ([@bib7]; [@bib35]).

Besides the well-known motor problems, PD patients can develop a variety of disabling non-motor symptoms ([@bib19]), like psychosis, depression, hyposmia, rapid eye movement (REM) sleep behavior disorder and constipation, some of which can even occur prior to the first motor manifestations ([@bib12]). This has sparked a growing interest in probing non-motor aspects for early diagnosis. Gastro-intestinal (GI) dysfunction in PD has recently attracted a lot of attention in this respect ([@bib8]). Several studies have reported the presence of α-synuclein aggregates in the enteric nervous system (ENS), which controls GI function, in fixed biopsy material or postmortem tissue from PD patients ([@bib17]; [@bib33]; [@bib26]; [@bib6]) suggesting that the ENS is directly affected by the disease process. This finding also fueled the hypothesis that α-synuclein pathology may spread from the periphery to the brain. According to this theory, an ingested pathogenic agent would enter nerve fibers in the GI tract and initiate α-synuclein misfolding, which would then propagate in a prion-like fashion along the axons up to the dorsal motor nucleus of the vagus in the lower brainstem ([@bib2]; [@bib14]). Nevertheless, more recent studies have shown similar patterns of α-synuclein immunoreactivity in the ENS in a high percentage of neurologically unimpaired controls ([@bib40]; [@bib11]; [@bib13]). Given the current debate about the potential utility of enteric α-synuclein immunohistochemistry as a biomarker for PD ([@bib40]; [@bib31]), new approaches are warranted to measure the involvement of the ENS in PD.

So far, not a single report has investigated the functionality of enteric neurons in PD patients. The general aim of this study was to examine the functionality of living enteric neurons of well-characterized PD patients. We used calcium imaging ([@bib5], [@bib4]) as a reliable proxy to assess neuronal function and mitochondrial imaging, to test the functionality of enteric neurons and mitochondria in freshly isolated submucous plexus preparations from PD patients and controls ([Figure 1](#fig1){ref-type="fig"}).10.7554/eLife.26850.002Figure 1.Schematic representation of the experimental strategy.Gastroduodenoscopy was performed on clinically well-characterized PD patients and their healthy partners, and 8 biopsies of the duodenum were taken per subject. The submucous plexus was peeled away from the mucosal epithelium and was used for live imaging techniques (Ca^2+^ or mitochondrial imaging) followed by post-hoc immunohistochemistry for confirmation of neuronal identity. In addition, the submucous plexus was isolated from 3 fresh biopsies per subject and immediately processed for immunohistochemistry (without live imaging) and numbers of neurons and ganglia were counted per biopsy (not indicated in the schematic).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.002](10.7554/eLife.26850.002)

Results {#s2}
=======

Study population {#s2-1}
----------------

We recruited 15 couples, each consisting of a PD patient and his or her healthy partner. This pairwise recruitment allowed within-pair comparisons to better control for variability in diet, lifestyle and other environmental factors. Demographic and clinical characteristics are summarized in [Table 1](#tbl1){ref-type="table"} and [Supplementary file 1](#SD10-data){ref-type="supplementary-material"}. As in most clinical PD studies, the majority of PD participants were male. PD patients and controls were age-matched and disease duration ranged from 2 to 17 years. All PD patients were under treatment with oral dopaminergic medication. None were treated with apomorphine, levodopa-carbidopa intestinal gel or deep brain stimulation. Three patients had levodopa-induced dyskinesias, five had early morning dystonia and two had daytime motor fluctuations. None of the patients had a first-degree relative with PD, except possibly one whose mother had allegedly developed tremor around the age of 90 years. Six of the 15 patients had disease onset under the age of 46 years. Genetic analysis of the *PARK2* gene was performed in 5 of these 6 patients, but no mutations were found.10.7554/eLife.26850.003Table 1.Demographic and clinical characterization of PD patients and controls Mean ± SD are shown with associated p-value (non-parametric Wilcoxon T-test^a^ \| Wilcoxson T-test ^b^ \| Chi squared test ^c^).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.003](10.7554/eLife.26850.003)Control subjects\
(n = 15)PD patients\
(n = 15)p-valueGender (M:F)4: 1111: 40.01 (\*) ^C^Age57.8 ± 2.6\
(range: 44--76)58.9 ± 9.2\
(range: 45--71)0.40 ^a^SCOPA total5.6 ± 2.7\
(range: 2--10)12.3 ± 9.2\
(range: 2--32)0.03 (\*) ^a^SCOPA GI0.9 ± 0.80\
(range: 0--2)2.7 ± 2.29\
(range: 0--8)0.02 (\*) ^b^Disease duration (years)-7.8 ± 3.9\
(range: 2--17)UPDRS III off\
(disease severity)-23.3 ± 10.0\
(range: 12--46)Age at onset (years)-51.1 ± 9.4\
(range: 36--69)Hoehn-Yahr (off)-2\
(IQR: 2--5)LED (mg)-684.1 ± 388.5\
(range: 205--1740)MMSE-29.6 ± 0.9[^3]

Interestingly, although presence of autonomic and GI symptoms was not an inclusion criterion, PD patients had significantly more autonomic and GI symptoms than controls ([Table 1](#tbl1){ref-type="table"}).

Ca^2+^ signalling properties of submucous neurons do not differ between PD patients and controls {#s2-2}
------------------------------------------------------------------------------------------------

Neurons were identified based on their specific morphology, localization in a ganglion and characteristic Fluo-4 loading ([Figure 2A](#fig2){ref-type="fig"}, left), as previously described ([@bib5], [@bib4]), and neuronal viability was assessed using a short high K^+^ depolarization (10 s, 75 mM K^+^) ([Figure 2A](#fig2){ref-type="fig"}, left) ([Video 1](#media1){ref-type="other"}), which induced a transient rise in intracellular calcium \[Ca^2+^\]~i~ ([Figure 2A](#fig2){ref-type="fig"}, middle). Post-hoc immunostaining for the neuronal markers HuCD and NF200 confirmed the neuronal identity of the cells selected during the live recordings ([Figure 2A](#fig2){ref-type="fig"}, right). In controls, 57.3 ± 29.5% of neurons displayed a transient change in Fluo-4 intensity (with maximum amplitude of 3.6 ± 2%, n = 15.6 ± 2.9 neurons per subject) upon depolarization with high K^+^. No significant difference was found when compared to PD patients, where both the number of high K^+^ responding neurons (49.5 ± 28.7%, p=0.47) and the \[Ca^2+^\]~i~ transient amplitudes (2.8 ± 3%, p=0.37, n = 11.9 ± 1.9 neurons per patient) were similar ([Figure 2B](#fig2){ref-type="fig"}). The percentage of responding neurons and \[Ca^2+^\]~i~ transient amplitudes in the PD group did not correlate with age, GI symptoms (as measured by the Scale for Outcomes in Parkinson\'s disease for Autonomic Symptoms (SCOPA-AUT), disease duration or disease severity (as assessed by Unified Parkinson's Disease Rating Scale (UPDRS) part III off medication ([Supplementary file 2](#SD11-data){ref-type="supplementary-material"}).10.7554/eLife.26850.004Figure 2.Ca^2+^signalling in submucous neurons in biopsies from PD patients and controls.(**A**.) Representative examples calcium imaging (left) and posthoc immunohistochemical staining (right). A typical example of submucous ganglia (PD and control) loaded with Fluo-4 is shown (left) as well as typical Ca^2+^ traces (normalized to the fluorescence at time zero F/F~0~) of single submucous neurons depolarized with a high K^+^ stimulus (represented as grey bar). The green and red traces are 2 random examples, the black trace is the background value. The panels on the right show the correlated post-hoc immunostaining for enteric neuronal markers (Green: HuCD (neuronal cell bodies); Magenta: NF200 (intermediate neurofilament 200: neuronal fibers). The inset shows a magnification of the selected ganglion (dashed square). The arrow (neuronal cell bodies) and arrowheads (neuronal fibers) point to the same structures in both immunohistochemical and corresponding Fluo-4 images (left). (**B**.) Summary data plots showing the percentage of responding neurons (top row) and maximum peak amplitude ∆F/F~0~ (%) (bottom row) for high K^+^, DMPP and electrical stimulation. The individual data points represent a patient or control for which all individual neuronal responses were averaged. (NS, not significantly different, non-parametric Wilcoxon T-test; p-values: % of responders; High K^+^=0.23, DMPP = 0.88, ES = 0.99 \| amplitudes: High K^+^=0.57, DMPP = 0.99, ES = 0.81).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.004](10.7554/eLife.26850.004)10.7554/eLife.26850.005Figure 2---source data 1.Calcium imaging % responders.GraphPad file with the corresponding values and graphs of the % of responders from the calcium imaging for the different stimuli HighK^+^, DMPP and electrical field stimulation (panel B, top graphs).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.005](10.7554/eLife.26850.005)10.7554/eLife.26850.006Figure 2---source data 2.Calcium imaging amplitude.GraphPad file with the corresponding values and graphs of the amplitude from the calcium imaging for the different stimuli HighK^+^, DMPP and electrical field stimulation. (panel B, lower graphs).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.006](10.7554/eLife.26850.006)Video 1.Calcium imaging in human submucous neurons.This movie shows a representative recording of Fluo-4 intensity changes in 2 human submucous ganglia (the ganglion on the right holds 2, while the one the left contains 5 neurons) during high K^+^ stimulation (10 s). The movie, which is representative for both groups (patients and controls) was taken from a PD patient sample. The original recording was deconvolved using Huygens software and movies generated using IGOR pro and ImageJ.**DOI:** [http://dx.doi.org/10.7554/eLife.26850.007](10.7554/eLife.26850.007)10.7554/eLife.26850.007Video 2.Mitochondrial imaging in the human submucous plexus.TMRE-labeled mitochondria in a submucous ganglion of a control subject are shown as well as the selection of mitochondria that are color-coded for intensity (see also [Figure 3A](#fig3){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.008](10.7554/eLife.26850.008)10.7554/eLife.26850.008Video 3.Mitochondrial imaging in the human submucous plexus.Movie of TMRE-labeled mitochondria in a submucous ganglion of a PD patient. The TMRE intensity variations over time are shown as well as the 3D mask (in green, appearing half way in the movie) that is used to calculate the mitochondrial density in ganglia (see also [Figure 4A](#fig4){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.009](10.7554/eLife.26850.009)10.7554/eLife.26850.009Video 4.Mitochondrial imaging in the human submucous plexus.Movie of TMRE-labeled mitochondria in a submucous ganglion of a control subject, showing TMRE fluctuations, selection of the ganglionic volume (3D mask) and mitochondrial volume detection (yellow) and spot detection (cyan) (see also [Figure 4](#fig4){ref-type="fig"} panels A1-4).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.010](10.7554/eLife.26850.010)10.7554/eLife.26850.010

In addition to high K^+^ depolarization we also used two more physiological stimuli to assess neuronal function: 1,1-dimethyl-4-phenylpiperazinium (DMPP), a nicotinic acetylcholine receptor agonist, as fast excitatory transmission in the ENS occurs mainly via acetylcholine on nicotinic receptors; and trains of electrical pulses applied to the fiber strands in the submucous plexus. However, neither for DMPP nor for electrical stimulation, differences in percentages of responding neurons or response amplitudes were found ([Figure 2B](#fig2){ref-type="fig"}).

Mitochondrial membrane potentials of submucous neurons are similar in PD patients and controls {#s2-3}
----------------------------------------------------------------------------------------------

To assess mitochondrial membrane potential, submucous ganglia were injected with Tetramethylrhodamine, ethyl ester (TMRE) and 3D confocal recordings were made and quantified using Andor iQ and IMARIS ([Figure 3A](#fig3){ref-type="fig"}). First, the average intensity (in arbitrary values) was determined in recordings made at room temperature (RT). The TMRE signals at RT were similar in both groups ([Figure 3B](#fig3){ref-type="fig"}) and did not correlate with age, Gl symptoms, disease duration or severity of PD patients ([Supplementary file 3](#SD12-data){ref-type="supplementary-material"}). To monitor mitochondrial membrane potential changes, preparations were kept at 37°C while TMRE signals were measured continuously over several minutes([Videos 2](#media2){ref-type="other"}--[3](#media3){ref-type="other"}). The intensity of the TMRE staining fluctuated substantially, indicating that both in PD patients and controls mitochondrial potentials were dynamically changing ([Figure 3C--D](#fig3){ref-type="fig"}). Here again, TMRE intensity fluctuations were not significantly different between PD patients and controls ([Figure 3E](#fig3){ref-type="fig"}), without any correlations with the clinical characteristics of PD patients ([Supplementary file 3](#SD12-data){ref-type="supplementary-material"}).10.7554/eLife.26850.011Figure 3.Mitochondrial membrane potential measurements in the submucous plexus of PD patients and controls.(**A**.) Representative example of a TMRE injection in the submucous plexus of a control subject. A subset of mitochondria was selected to show the TMRE intensity differences (as color-coded) in individual mitochondria. (**B**.) Summary data plot of the TMRE intensity in mitochondria of patients and controls (NS, not significantly different, p-value=0.49 (non-parametric Wilcoxon T-test). (**C**.) Example of a time series (900 s) of color-coded TMRE intensity fluctuations in individual mitochondria (see selection in **A**.). (**D**.) Graphs showing TMRE intensity variations (%) over time of three individual mitochondria of control and PD patient, suggesting similar dynamics in patients and controls. (**E**.) Summary data plot of the average TMRE intensity fluctuations for controls and PD patients. (NS, not significantly different, p-value=0.99, non-parametric Wilcoxon T-test).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.011](10.7554/eLife.26850.011)10.7554/eLife.26850.012Figure 3---source data 1.Mitochondrial membrane potential measurements.GraphPad file with the corresponding values and graphs of the mitochondrial membrane potential measurements (panel B and E).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.012](10.7554/eLife.26850.012)10.7554/eLife.26850.013Figure 3---figure supplement 1.Mitochondrial TMRE destaining in the submucous plexus after addition of FCCP.Representative graph showing the average intensity in arbitrary units (A.U.) of 16 mitochondria labeled with TMRE and imaged at 37°C before and after addition of 3 µM FCCP. The complete destaining in the presence of FCCP indicates that TMRE specifically labeled mitochondria.**DOI:** [http://dx.doi.org/10.7554/eLife.26850.013](10.7554/eLife.26850.013)

Mitochondrial volume and numbers in submucous neurons do not differ between PD patients and controls {#s2-4}
----------------------------------------------------------------------------------------------------

Given the similarity of TMRE loading between PD patients and controls and the problems with mitotracker green (MTG) loading (see Materials and methods), we used the TMRE signals recorded at RT to also compare mitochondrial volume and numbers ([Figure 4A](#fig4){ref-type="fig"}). We first analysed the total mitochondrial volume and number of mitochondria in a selected 3D mask surrounding the injected ganglion ([Figure 4A](#fig4){ref-type="fig"}). The volumes of the outlined ganglia were not significantly different between the 2 groups (data not shown), nor was the total mitochondrial volume inside the selection ([Figure 4B](#fig4){ref-type="fig"}). The mitochondrial volume did not significantly correlate with age, GI symptoms, disease duration or severity of PD patients ([Supplementary file 3](#SD12-data){ref-type="supplementary-material"}). In addition to total mitochondrial volume, we also analysed mitochondrial density (number of mitochondria within the ganglion outline). This parameter was again not significantly different between the two groups ([Figure 4C](#fig4){ref-type="fig"}) and did not correlate with clinical characteristics in the PD group ([Supplementary file 3](#SD12-data){ref-type="supplementary-material"}). Lastly, we compared average volume of individual mitochondria and, similarly to other mitochondrial parameters, this did not significantly differ between the two groups ([Figure 4D](#fig4){ref-type="fig"}), nor was it correlated with any of the clinical parameters ([Supplementary file 3](#SD12-data){ref-type="supplementary-material"}) ([Video 4](#media4){ref-type="other"}).10.7554/eLife.26850.014Figure 4.Mitochondrial number and volume in the submucous plexus of PD patients and controls.(**A**.) Representative example of a submucous plexus injected with TMRE for a control (left) and PD patient (right). The 3D mask drawn around the injected ganglion is shown in grey. The inside of this volume is enlarged in panels **A1-4** with an additional magnification of a selected subset (dashed square). Panels **A1-4** represent an example of mitochondrial volume detection (A2), mitochondrial spot detection (A3) and overlay of both (A4). (**B**.) Schematic representation of the total mitochondrial volume detection within the 3D mask and summary data plot of the volume (mitochondrial/3D mask) ratio quantification. (**C**.) Schematic representation of mitochondrial spot detection and summary data plot of the quantification (mitochondrial density (\#/1000 µm³). (**D**.) Schematic representation of the segmentation process (color-coded for mitochondrial size) to quantify the average volume (µm³) of single mitochondria and a summary data plot of the quantification in controls versus patients. (NS, not significantly different, p-values (non-parametric Wilcoxon T-test); mitochondrial volume ratio = 0.65, mitochondrial density = 0.00.16, mitochondrial volume = 0.30).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.014](10.7554/eLife.26850.014)10.7554/eLife.26850.015Figure 4---source data 1.Mitochondrial ratio.GraphPad file with the corresponding values and graph of mitochondrial ratio measurements (panel B).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.015](10.7554/eLife.26850.015)10.7554/eLife.26850.016Figure 4---source data 2.Mitochondrial density.GraphPad file with the corresponding values and graph of mitochondrial density measurements (panel C).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.016](10.7554/eLife.26850.016)10.7554/eLife.26850.017Figure 4---source data 3.Mitochondrial volume.GraphPad file with the corresponding values and graph of mitochondrial volume measurements (panel D).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.017](10.7554/eLife.26850.017)

The submucous plexus contains similar numbers of ganglia and neurons in PD patients and controls {#s2-5}
------------------------------------------------------------------------------------------------

Finally, we counted the number of neurons per ganglion, total number of neurons per biopsy and number of ganglia per biopsy in both groups based on immunofluorescent staining ([Figure 5A](#fig5){ref-type="fig"}). None of these parameters differed between the two groups ([Figure 5B--D](#fig5){ref-type="fig"}). No correlations were found between these counts and age, GI symptoms, disease duration or disease severity of PD patients ([Supplementary file 4](#SD13-data){ref-type="supplementary-material"}). We also tested whether α-synuclein aggregates were present in the samples using an antibody against α-synuclein. However, the staining patterns were indistinguishable between PD patients and controls ([Figure 6](#fig6){ref-type="fig"}).10.7554/eLife.26850.018Figure 5.Quantification of neuron and ganglia numbers in the submucous plexus of PD patients and controls.(**A**.) Representative immunofluorescent staining of submucous plexus of a control and PD patient stained for the pan-neuronal marker HuCD (green) and neuronal filament marker NF200 (Magenta). Bars: 50 μm. (**B**.) Graph showing quantification of number of neurons per ganglion. (**C**.) Graph showing quantification of total number of neurons per biopsy. (**D**.) Graph showing quantification of number of ganglia per biopsy. (NS, not significantly different (non-parametric Wilcoxon T-test), p-values; \# neurons/ganglion = 0.86, \# neurons/biopsy = 0.17 (non-parametric Wilcoxson T-test), \# ganglia/biopsy = 0.24).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.018](10.7554/eLife.26850.018)10.7554/eLife.26850.019Figure 5---source data 1.Number of neurons per ganglia.GraphPad file with the corresponding values and graph of number of neurons per ganglia (panel B).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.019](10.7554/eLife.26850.019)10.7554/eLife.26850.020Figure 5---source data 2.Number of neurons per biopsy.GraphPad file with the corresponding values and graph of number of neurons per biopsy (panel C).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.020](10.7554/eLife.26850.020)10.7554/eLife.26850.021Figure 5---source data 3.Number of ganglia per biopsy.GraphPad file with the corresponding values and graph of number of neurons per biopsy (panel D).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.021](10.7554/eLife.26850.021)10.7554/eLife.26850.022Figure 6.α-synuclein staining in the submucous plexus of PD patients and controls.Top and bottom rows show three single slice confocal and deconvolved images of a representative immunofluorescent staining in the submucous plexus of a control (top) and PD patient (bottom) stained for the pan-neuronal marker HuCD (green) and α-synuclein (magenta). A neuronal fiber staining (yellow: NF200 in bottom and peripherin in top row) was added to help delineating the submucous ganglion. No differences in α-synuclein staining patterns in PD patients and controls could be detected. Bars: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.26850.022](10.7554/eLife.26850.022)

Discussion {#s3}
==========

In this study, we assessed the functionality of enteric neurons in PD patients and age-matched healthy controls using live imaging. Because PD patients often have GI problems, the ENS has been the subject of intensive study in the PD field for several decades ([@bib29]; [@bib16]; [@bib42]). A major driving force was the quest for a biomarker to help diagnose PD in its premotor phase. In parallel, the hypothesis arose that the GI tract could be a starting point from where PD pathology propagates to the brain ([@bib2]; [@bib14]; [@bib23], [@bib24]; [@bib20], [@bib21]). Several groups have focused on immunohistochemical detection of α-synuclein aggregates in fixed GI tissue as a possible diagnostic biomarker for PD, with an emphasis on (sub)mucosal layers as these are accessible via endoscopy ([@bib33]; [@bib2]; [@bib42]; [@bib15]; [@bib37]; [@bib18]; [@bib27], [@bib28]; [@bib34]). So far, the outcome of these studies has been variable, possibly due to methodological differences ([@bib40]; [@bib31]). Instead of searching for α-synuclein aggregation, only one study recently assessed mitochondrial morphology in the ENS of PD patients, but again using immunohistochemistry on fixed biopsies. We took a different approach and used live imaging to determine whether the submucous plexus in PD patients is functionally different from controls.

First, we found no significant differences in enteric neuronal Ca^2+^ responses to various stimuli or in mitochondrial membrane potential, number and volume between the two populations. Second, numbers of neurons and ganglia in the biopsies were similar in PD patients and controls, indicating that the similar neuronal response patterns were not due to loss of the most vulnerable and dysfunctional neurons earlier in the disease. Last, we did not find differences in submucosal α-synuclein staining patterns between PD patients and controls.

Although GI symptoms were not an inclusion criterion for PD patients in this study, the PD patients had more GI symptoms than controls, in line with previous data ([@bib8]). Our finding of preserved neuronal functionality in these patients suggests that GI symptoms in PD do not arise from disturbed submucous neuronal function. Instead, GI symptoms may possibly be caused by impaired function of neurons of the myenteric plexus, the deeper nerve layer innervating the GI muscle. The submucous plexus predominantly controls secretion, whereas the myenteric plexus predominantly controls motility ([@bib9]) and may thus be more involved in delayed gastric emptying and constipation in PD. However, it is not possible to safely sample the myenteric plexus with routine endoscopic biopsies because of the risk of bleeding. Another possible anatomic substrate for GI dysfunction in PD is the dorsal motor nucleus of the vagus in the brainstem, which is heavily affected by PD pathology ([@bib3]) and innervates neurons of the myenteric plexus via vagal nerve connections.

It has been suggested that the GI tract may be a site of initiation of PD. According to this hypothesis, an ingested pathogen may induce α-synuclein misfolding in submucous neurons, followed by retrograde axonal and transsynaptic propagation of α-synuclein misfolding via the vagus nerve to the brainstem ([@bib2]; [@bib14]). Chronic oral ingestion of low-dose rotenone in mice was reported to trigger α-synuclein accumulation in ENS ganglia and subsequently in the dorsal motor nucleus of the vagus nerve and substantia nigra, a sequence that was interrupted by vagotomy ([@bib23], [@bib24]). Supporting this hypothesis, an epidemiological study reported that truncal vagotomy may be associated with a decreased risk of subsequent PD ([@bib39]), although this link is still controversial ([@bib36]). Our data in living human neurons do not support this theory, as it seems unlikely that an ingested pathogen would induce toxicity in myenteric neurons and vagal nerve fibres while preserving the functionality of submucous neurons, which are located more closely to the gut lumen and whose fibres extend into the mucosa.

To our knowledge, this study is the first to investigate the functionality of living enteric neurons of patients with PD or any other neurodegenerative disease at the cellular and subcellular level. Many groups have modelled neurodegenerative diseases by generating neurons from patient fibroblasts via induced pluripotent stem cells (iPSCs) ([@bib30]), but it is still uncertain how faithfully iPSC-derived neurons mimic the behavior of endogenous primary neurons. Previous studies of the ENS in human PD have generally focused on patterns of α-synuclein immunoreactivity in fixed tissue. It should be kept in mind that the well-known Braak staging of PD is also exclusively based on detection of Lewy pathology but its link with neuronal function is still unclear ([@bib1]). Ideally, future research into the progression of PD should also assess neuronal function and not just Lewy pathology.

Strengths of this study were its prospective design and the blinding of the investigators during imaging and data analysis. PD patients were clinically well-characterized, allowing us to search for correlations of cellular physiological and clinical parameters. Moreover, recruitment of the partners of PD patients as controls made it possible to make within-pair comparisons and minimize variability due to diet, lifestyle and other environmental factors. This is important in the light of recent data showing that cohabitation results in overlapping gut microbiome profiles ([@bib43]) and that the composition of the gut microbiome may be related to the clinical manifestations of PD ([@bib32]).

Our study also has some limitations. The number of subjects was relatively small. Power calculations for this study were difficult because live imaging of PD enteric neurons has never been performed before and no data were available to reliably estimate expected differences and standard deviations. Patients with young-onset PD were somewhat overrepresented, possibly reflecting the greater willingness of young PD patients to participate in a demanding study. Another limitation was that the PD and control groups were not gender-matched. This was a consequence of the pairwise recruitment in combination with the fact that the majority of PD participants, as in most clinical PD studies, were male. Another criticism could be that the Ca^2+^ and mitochondrial imaging assays may not be sensitive enough to detect subtle impairments in neuronal function. Nevertheless, using the same technology, we previously found alterations in submucous neurons in functional dyspepsia patients ([@bib5]), demonstrating the robustness of the techniques to detect changes, even subtle, in disease conditions. Another limitation is that we were unable to sample and analyze myenteric neurons due to safety reasons, as discussed above. It is also possible that the duodenum was not the optimal site for detection of neuronal changes in PD. However, we precisely chose a proximal GI site based on evidence that α-synuclein aggregation in the ENS in PD is deposited with a rostrocaudal gradient ([@bib40]). Moreover, proximal portions of the GI tract receive stronger vagal innervation than distal regions ([@bib31]) which, in view of the hypothesis that the vagus nerve transmits PD pathology, makes this region especially interesting. Also, duodenal endoscopy is better tolerated and requires less demanding patient preparation compared to colonoscopy. Finally, we cannot exclude the possibility that the duodenal submucosal plexus in PD patients is affected in a non-uniform, 'patchy' fashion and that we missed affected ganglia due to spatial sampling error.

In conclusion, we have applied live imaging techniques to investigate neuronal physiology in primary neurons from PD patients. Our findings suggest that GI symptoms in PD do not arise from dysfunction of submucous neurons. Furthermore, our data do not support the theory that the disease process of PD initiates in the submucous layers of the ENS and spreads from there to the brain.

Materials and methods {#s4}
=====================

Study population {#s4-1}
----------------

Fifteen patients with PD and fifteen healthy age-matched controls were recruited in pairs in the Movement Disorders Clinic of University Hospitals Leuven. Each pair consisted of a PD patient and his/her healthy partner. We recruited pairwise in order to allow within-pair comparisons and minimize variability due to diet, lifestyle and other environmental factors. Inclusion criterion for PD patients was diagnosis of PD according to the Gelb criteria ([@bib10]). GI symptoms were not a requirement for inclusion. Exclusion criteria for PD patients were: cognitive impairment that, in the opinion of the treating neurologist, interfered with the ability to fully understand the patient information brochure; and presence of GI disorders unrelated to PD. Exclusion criteria for the controls were GI and neurological diseases. All PD and control subjects completed the SCOPA-AUT, a questionnaire designed to assess autonomic (including GI) symptoms in PD patients ([@bib41]), within one month before the endoscopic procedure. On the morning of the gastroduodenoscopy disease severity was assessed in the PD patients by a movement disorders neurologist by means of UPDRS part III and Hoehn-Yahr (HY) scale in practically defined 'off' state, that is, at least 12 hr after the last intake of medication. UPDRS parts I, II and IV and Mini Mental State Examination (MMSE) were also completed. Levodopa-equivalent daily dose (LED) was calculated as described ([@bib38]). Disease duration was based on the onset of the first motor symptom as reported by the patient. On the morning of the procedure, control subjects were also clinically assessed by the movement disorders neurologist to exclude parkinsonism. The ethics committee of the University Hospitals Leuven approved the study and all subjects gave written informed consent and consent to publish according to the declaration of Helsinki.

Gastroduodenoscopy and biopsy preparation {#s4-2}
-----------------------------------------

An experienced endoscopist at the Gastroenterology unit of the University Hospitals Leuven obtained 8 biopsies from the second part of the duodenum from each PD patient and control. Each pair underwent endoscopy on the same day immediately one after another in random order. All subjects had a macroscopically normal upper GI tract, except for one control with minor reflux esophagitis. The duodenal biopsies were immediately immersed in oxygenated ice-cold Krebs solution (in mM: 120.9 NaCl, 5.9 KCl, 1.2 MgCl~2~, 2.5 CaCl~2~, 11.5 glucose, 14.4 NaHCO~3~, and 1.2 NaH~2~PO~4~) and coded. All subsequent tissue manipulations, experiments and data analyses were performed by investigators blinded to the disease status (PD versus control) of the subject. The submucous plexus was removed from the mucosal epithelium by microdissection, as described previously ([@bib4]), and used the same day for live calcium (Ca^2+^) or mitochondrial imaging. A schematic overview of the experimental workflow is presented in [Figure 1](#fig1){ref-type="fig"}.

Calcium imaging {#s4-3}
---------------

Submucous plexus preparations (2 per subject) were loaded at RT for 20 min with the fluorescent Ca^2+^ indicator Fluo-4 AM (1 µM, Molecular Probes, Merelbeke, Belgium) in Krebs buffer containing 0.01% Cremophor EL surfactant agent (Fluka Chemika, Buchs, Switzerland). After rinsing, tissues were imaged as previously described ([@bib4]).

To elicit neuronal activity, we used three different stimuli: first, a brief high K^+^ (10 s, 75 mM) induced depolarization was applied via a local perfusion pipette to induce a sharply rising Ca^2+^ transient and test neuron viability. Second, fibre tracts were electrically stimulated by trains (2 s, 20 Hz) of 300 μs electrical pulses (Grass Instruments, Rhode Island, USA) applied via a tungsten electrode (diameter 50 μm). Third, the nicotinic cholinergic receptor agonist DMPP (10 μM, Fluka Chemika, Buchs, Switzerland) was locally perfused for 20 s.

Images were collected using Till Vision software (TILL Photonics, Gräfelfi, Germany) and analysis was performed using custom-written macros in IGOR PRO (Wavemetrics, Lake Oswego,OR). To remove drift and movement artefacts due to perfusion, the image stack was registered to the first image. Regions of interest (ROIs) were drawn over each neuron and fluorescence intensities were calculated, normalized and expressed as an F/F~0~ ratio (with F~0~ being the baseline fluorescence). Transient \[Ca^2+^\]~i~ peaks were considered if they exceeded the baseline plus 5 times the intrinsic noise level. The percentage of responsive cells was determined. The maximum \[Ca^2+^\]~i~ peak amplitude was calculated as a percentage change above baseline.

Mitochondrial imaging {#s4-4}
---------------------

Submucous plexus preparations (3 per subject) were pinned flat in a Sylgard (Dow Corning) containing dish. A glass microinjection capillary (pulled on a P87 Sutter Instruments pipette puller) filled with TMRE (300 nM, Thermo Fischer, Merelbeke, Belgium) was navigated into a submucous ganglion using a pneumatic manipulator (Narishige, New York, USA). Local injection of the mitochondrial dye was essential in order to avoid background loading of connective tissues and cellular structures other than those of the submucous plexus. This approach differs from TMRE loading protocols in cellular monolayers ([@bib22]; [@bib25]). However, even though the TMRE concentration used in the injection pipette is relatively high, we assume that all observations were made in non-quenching TMRE mode, because after the topical injection (\~150 nl) the dye rapidly diffuses into a larger volume (dilution by a factor 40 if the volume of biopsy \[6 mm³\], or \~3.10^3^ if the recording bath volume 500 µl is considered). Moreover, image stacks were recorded in SMP structures away from the injection spot, to assure we recorded at lower concentrations than what was injected.

To test whether TMRE specifically labelled mitochondria, we used carbonyl cyanide-*4*-(trifluoromethoxy)phenylhydrazone (FCCP, 3 μM), a protonophore that quickly dissipates mitochondrial membrane potential. The complete destaining indicates that TMRE specifically labeled mitochondria ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

In an earlier preliminary set of experiments, Mitotracker green (10 μM, Life Technologies, Merelbeke, Belgium) was also injected in an attempt to determine mitochondrial volumes in a membrane potential-independent way. However, Mitotracker green did not diffuse from the injection spot and there was no spread of the dye in human tissue. The reason is unclear but most likely higher temperatures (37°C) are needed for the dye to spread uniformly. We therefore abandoned the Mitotracker green strategy and focused on single dye (TMRE) injections, and used the TMRE signals at RT to determine mitochondrial volume and density.

After injection, the tissues were imbedded in 1.5% low-melting point agarose dissolved in Krebs buffer, which allowed transfer of the preparations close and flat enough to a glass coverslip to be recorded from on an inverted spinning disk confocal microscope (Nikon Ti - Andor Revolution - Yokogawa CSU-X1 Spinning Disk (Andor, Belfast, UK)) with a Nikon 40x lens (LWD, NA 1.1, WI). For fast 3D stacks we used a Piezo Z Stage controller, and recorded both at RT (to analyze the morphology of the mitochondria) and at physiological temperatures (37°C) (to analyze dynamic mitochondrial membrane potential fluctuations). Image stacks were deconvolved using a theoretical point spread function based on the optical properties of the imaging system (pinhole spacing (6.33 µm) and backprojection radius (625 nm)) and stabilized using Huygens professional (SVI, Hilversum, The Netherlands). The background fluorescence was automatically estimated and corrected for using Huygens' default parameters as well as (when necessary) photo-bleaching, always assuming the first image to be the brightest.

Subsequently, the deconvolved image stacks were imported in IMARIS 8.0.1 (Bitplane, Zurich, Switzerland) to assess mitochondrial volume and intensity characteristics. First, a volume of interest was drawn around the injected ganglion, which was then used as a 3D mask, within which the spot and volume detection (absolute intensity thresholding) algorithms available in IMARIS were applied. Also mitochondrial intensity changes over time were analysed in the image stacks recorded at 37°C by tracking mitochondria over time. In this analysis, 500 mitochondria per volume were selected from the output of Imaris' spot detection algorithm, which sorted detected spots based on maximum intensity in the spot centre.

Immunohistochemistry {#s4-5}
--------------------

After Ca^2+^ imaging and mitochondrial analysis, the submucous plexus preparations were fixed for 30 min in 4% paraformaldehyde (PFA, Merck, Overijse, Belgium) for post-hoc immunohistochemical confirmation of neuronal identity. In addition, the submucous plexus was isolated from three fresh biopsies per subject (without live imaging) and immediately fixed in PFA for immunohistochemical analysis of numbers of ganglia, neurons per ganglion and numbers of non-ganglionic (individual) neurons, as described earlier ([@bib4]).

Primary antibodies against two typical enteric neuron markers: neurofilament NF200 (chicken anti-NF200 1/50000; Abcam, Cambridge, UK, RRID: [AB_2149618](https://scicrunch.org/resolver/AB_2149618)) and HuCD (mouse anti-HuCD 1/500; Molecular Probes, Merelbeke, Belgium, RRID: [AB_221448](https://scicrunch.org/resolver/AB_221448)), were used after 2 hr (at RT) in blocking buffer containing 0.5% Triton X-100 (Thermo Fischer, Merelbeke, Belgium) and 4% serum matched to the host of the secondary antibody. After three cycles of washing (PBS), fluorescently labelled secondary antibodies were then added for 2 hr (at RT). After final washing (PBS), tissues were mounted on a microscope slide in citifluor (Citifluor Ltd.,Leicester,UK). Confocal images were recorded using a Zeiss LSM 780 confocal microscope (Zeiss, Belgium). Additionally, α-synuclein (SC-7011-R, Santa Cruz Biotechnology, Dallas, Texas, US, RRID:[AB_2192953](https://scicrunch.org/resolver/AB_2192953)) antibodies were used on one fixed submucous plexus of each subject. Confocal images and blinded analysis were performed to evaluate labelling patterns and possible aggregation in these tissues.

Statistical analysis {#s4-6}
--------------------

All experiments and analyses were performed in a blinded fashion. Investigators were unblinded only after the analysis of imaging data for all subjects had been finalized. All results are presented as mean ± SD, except for Hoehn-Yahr scores, which are presented as median and interquartile ranges. Differences between groups were analysed using paired tests (for details see below). Imaging parameters were also correlated with clinical characteristics (age, SCOPA GI symptoms, UPDRS III off, disease duration) using linear correlations. Based on data distributions, there was no reason to assume any higher order relations. Non-parametric (Wilcoxon test/Spearman correlation) tests were used based on the outcome of Shapiro-Wilk tests for normal data distribution. A Bonferroni correction was used to correct for multiple testing.
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###### Clinical characteristics of individual PD patients.

Clinical data of individual PD patients. SCOPA total, \*Patient six entered 'not applicable' for the 2 SCOPA items related to sexual function. Mean ± SD are shown. For Hoehn-Yahr scores, median and interquartile range are shown instead of average and SD.

**DOI:** [http://dx.doi.org/10.7554/eLife.26850.023](10.7554/eLife.26850.023)

10.7554/eLife.26850.024

###### Correlation between Ca^2+^ imaging data and PD characteristics

Spearman R-values of correlations between Ca^2+^ imaging parameters and clinical characteristics of PD patients (gray shaded rows) and where applicable (age, SCOPA) of controls (white rows).

**DOI:** [http://dx.doi.org/10.7554/eLife.26850.024](10.7554/eLife.26850.024)

10.7554/eLife.26850.025

###### Correlations between mitochondrial imaging data and PD characteristics

Spearman R-values of correlations between mitochondrial imaging parameters and clinical characteristics of PD patients (gray shaded rows) and where applicable (age, SCOPA) of controls (white rows).

**DOI:** [http://dx.doi.org/10.7554/eLife.26850.025](10.7554/eLife.26850.025)

10.7554/eLife.26850.026

###### Correlations between immunohistochemical data and PD characteristics

Spearman R-values of immunofluorescent counting correlated with clinical characteristics of the PD patients (gray shaded rows) and where applicable (age, SCOPA) of controls (white rows).

**DOI:** [http://dx.doi.org/10.7554/eLife.26850.026](10.7554/eLife.26850.026)
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National Institute of Neurological Disorders and Stroke, National Institutes of Health
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Live calcium and mitochondrial imaging in the enteric nervous system of Parkinson patients and controls\" for consideration by *eLife*. Your article has been favorably evaluated by a Senior Editor and four reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Please address the experimental concerns of reviewer \#3 and the other concerns of all the reviewers by editing the text. For example, as noted by several reviewers, the authors should clearly state that a limitation of their study is that they did not examine the myenteric plexus, unless they can provide literature support that the submucosal plexus they sampled has been shown previously to display α-synuclein aggregates. Reviewers \#2 and \#4 point about \"patchiness\" is also important to consider and comment on.

The revisions will be assessed by the handling Reviewing Editor but won\'t necessarily be evaluated by all of the original reviewers.

*Reviewer \#1:*

Using powerful live cell imaging methods of control and PD patient duodenum biopsies, Desmet and colleagues find that calcium handling, mitochondrial functions and number and a-synuclein immunostaining are normal in submucosal enteric neurons. The methods and data collected seem clear and the manuscript is very well written. The main problem is that myenteric plexus neurons, that are implicated in the constipation phenotype of PD patients, lie too deep for analysis. Thus, the submucosal plexus results are less that definitive evidence arguing against several gut to brain hypotheses. Nevertheless, the results do impact important issues regarding PD diagnosis and etiology.

*Reviewer \#2:*

Gastrointestinal dysfunction is a prominent non-motor feature of Parkinson\'s disease (PD). The alimentary tract as a whole is affected, with abnormal salivation, dysphagia, delayed gastric emptying, constipation and defecatory dysfunction. The underlying mechanisms are poorly understood, but it has been suggested that they may have something to do with the abnormal aggregation of α-synuclein in the enteric nervous system. The presence of Lewy pathology in the enteric nervous system in PD has been known since 1984. It is found in both Auerbach\'s and Meissner\'s plexuses. One school of thought believes that α-synuclein-containing inclusions first appear in the enteric nervous system, from where they progress to brain regions, such as the dorsal motor nucleus of the vagus nerve and the substantia nigra. A pathogen may penetrate the gut epithelium and enter axons of the enteric neurons in the myenteric plexus (Auerbach\'s plexus), which controls the activity of the smooth muscles of the gut and/or axons of the submucosal plexus (Meissner\'s plexus), which regulates mucosal secretion and blood flow. The present study used live imaging of neurons from the duodenum, of patients with PD and controls obtained through gastroduodenoscopy. All the patients with PD were undergoing treatment with oral dopaminergic medication. The authors investigated calcium signalling properties of submucous neurons, mitochondrial membrane potentials of these neurons, mitochondrial volumes and numbers, as well as numbers of nerve cells. No differences with controls were found, nor were there any α-synuclein aggregates. This study, which used a reasonable number of patients with PD and several innovative techniques, suggests that submucosal neurons of the duodenum were not functionally impaired and that gastrointestinal dysfunction in these patients must have had other reasons. It is widely believed that it is the myenteric plexus which mostly controls motility and dysfunction of which thus could thus play a role in constipation in PD. The absence of α-synuclein aggregates in endoscopic biopsies that do not include the myenteric plexus should be interpreted with caution. One must also bear in mind that these patients had clinical PD, with abundant α-synuclein inclusions in brain. What one cannot exclude is that the enteric nervous system was affected during the prodrome of PD, but did not have any more α-synuclein inclusions in the clinical phase. Of course, this study is limited by the fact that the authors only looked at duodenal biopsies. There might have been α-synuclein inclusions elsewhere. Is it possible that there were some in the duodenum as well, but that they were missed during gastroduodenoscopy?

*Reviewer \#3:*

The manuscript by Desmet et al. describes an important set of experiments examining the properties of live, human submucosal neurons taken from Parkinson\'s disease (PD) patients and spousal controls. These studies found no differences between PD submucosal neurons and controls in several assays, including apparent viability, neuronal density, cytosolic Ca^2+^ influx in response to depolarization, mitochondrial membrane potential, mitochondrial density or α-synuclein immunoreactivity. Given the widespread belief that PD originates in the GI tract and initially manifest as submucosal pathology, the results of this study, even though they are negative, are very important. From a technical standpoint, the studies are very nicely done and clearly illustrated. The manuscript is well-written (although the Discussion should be shortened), circumspect (e.g., the limitations of the study are clearly stated) and scholarly. I have only a few concerns.

• The TMRE measurements should be calibrated by using oligomycin and FCCP to hyperpolarize and depolarize mitochondria. Was TMRE at non-quenching concentrations?

• Using TMRE for the mitochondrial density estimates is a bit problematic because it brings mitochondrial membrane potential into the picture, whereas a mitochondrially targeted GFP or mitotracker green wouldn\'t have done so. I understand the need for a rapid, diffusible marker with the biopsies but the authors should discuss the limitations of this aspect of the study in the main body of the text.

• Was there any difference in mitochondrial morphology in the PD and control samples?

*Reviewer \#4:*

Desmet et al. investigate enteric neuronal function from duodenal biopsies in patients with Parkinson\'s disease and controls. The goal is to explore whether functional assays can detect evidence consistent with the established increased prevalence of GI symptomatology and predilection for α-synuclein pathology in the enteric nervous system. The experiments do not detect any differences between cases and spouse controls, based on calcium imaging, mitochondrial membrane potential, and assessments of mitochondrial numbers. None of the biopsies had demonstrable α-synuclein aggregate pathology, making it difficult to conclude whether the negative results might be due to sampling issues. While innovative, the negative results in this small cohort, allow only preliminary conclusions to be drawn at this stage. This manuscript is not appropriate for *eLife*, and would be better suited to a neurology journal.

Suggestions for improving the manuscript:

It would be helpful to discuss further whether prior studies have found synuclein pathology with similar frequency in the submucosal vs. myenteric plexus.

Consider the possibility that pathology and dysfunction of the ENS may be \"patchy\", complicating interpretation of studies of selective biopsies.

It would be interesting in the Discussion (or Introduction) to discuss any results from PD animal model studies of the GI tract.

The discussion could be shortened, and suggest caution not to overstate the conclusion given the many caveats: \"our findings... strong suggests that GI symptoms in PD do not arise from disturbed sub mucous neuronal function\".

The authors also overstate the degree of controversy surrounding enteric nervous system pathology in PD (e.g. Introduction, second paragraph). While there is certainly debate about the potential utility as a clinical biomarker and the best staining protocol, I believe most experts agree that the ENS is pathologically involved.

10.7554/eLife.26850.029

Author response

*Reviewer \#1:*

*Using powerful live cell imaging methods of control and PD patient duodenum biopsies, Desmet and colleagues find that calcium handling, mitochondrial functions and number and a-synuclein immunostaining are normal in submucosal enteric neurons. The methods and data collected seem clear and the manuscript is very well written. The main problem is that myenteric plexus neurons, that are implicated in the constipation phenotype of PD patients, lie too deep for analysis. Thus, the submucosal plexus results are less that definitive evidence arguing against several gut to brain hypotheses. Nevertheless, the results do impact important issues regarding PD diagnosis and etiology.*

As the myenteric plexus lies too deep to safely sample during endoscopy, our study indeed does not provide data on myenteric neurons. We agree with the reviewer that this is an important limitation. We already indicated this in the Discussion of the previous version of the manuscript and included this again in the revised manuscript: 'GI symptoms may possibly be caused by impaired function of neurons of the myenteric plexus, the deeper nerve layer innervating the GI muscle. The submucous plexus predominantly controls secretion, whereas the myenteric plexus predominantly controls motility, and may thus be more involved in delayed gastric emptying and constipation in PD. However, it is not possible to safely sample the myenteric plexus with routine endoscopic biopsies because of the risk of bleeding.'

To emphasize this limitation even more strongly, we have added the following statement to the Discussion: 'Another limitation of the study is that we were unable to sample and analyze myenteric neurons due to safety reasons, as indicated above.'

Nevertheless, we believe that our functional data on submucosal neurons are very relevant in the context of PD, even in the absence of myenteric plexus data, for three reasons:

1\) The submucosal plexus is located more closely to the gut lumen than the myenteric plexus. Considering the hypothesis that PD may be triggered by environmental pathogens that enter via the lumen, submucosal neurons would be more likely to be affected than myenteric neurons.

2\) Submucosal and myenteric neurons are synaptically and functionally connected. Based on the hypothesis of transsynaptic spread of pathological forms of α-synuclein, it would seem unlikely that one of these layers would be severely affected while the other would be intact.

3\) Several publications have reported abnormal α-synuclein aggregates in the submucosal plexus of PD patients (references 1-6 below). In fact, we have not found any evidence in the immunohistochemical literature suggesting that pathology in PD might selectively affect the myenteric plexus while sparing the submucosal plexus.

*Reviewer \#2:*

*Gastrointestinal dysfunction is a prominent non-motor feature of Parkinson\'s disease (PD). The alimentary tract as a whole is affected, with abnormal salivation, dysphagia, delayed gastric emptying, constipation and defecatory dysfunction. The underlying mechanisms are poorly understood, but it has been suggested that they may have something to do with the abnormal aggregation of α-synuclein in the enteric nervous system. The presence of Lewy pathology in the enteric nervous system in PD has been known since 1984. It is found in both Auerbach\'s and Meissner\'s plexuses. One school of thought believes that α-synuclein-containing inclusions first appear in the enteric nervous system, from where they progress to brain regions, such as the dorsal motor nucleus of the vagus nerve and the substantia nigra. A pathogen may penetrate the gut epithelium and enter axons of the enteric neurons in the myenteric plexus (Auerbach\'s plexus), which controls the activity of the smooth muscles of the gut and/or axons of the submucosal plexus (Meissner\'s plexus), which regulates mucosal secretion and blood flow. The present study used live imaging of neurons from the duodenum, of patients with PD and controls obtained through gastroduodenoscopy. All the patients with PD were undergoing treatment with oral dopaminergic medication. The authors investigated calcium signalling properties of submucous neurons, mitochondrial membrane potentials of these neurons, mitochondrial volumes and numbers, as well as numbers of nerve cells. No differences with controls were found, nor were there any α-synuclein aggregates. This study, which used a reasonable number of patients with PD and several innovative techniques, suggests that submucosal neurons of the duodenum were not functionally impaired and that gastrointestinal dysfunction in these patients must have had other reasons. It is widely believed that it is the myenteric plexus which mostly controls motility and dysfunction of which thus could thus play a role in constipation in PD. The absence of α-synuclein aggregates in endoscopic biopsies that do not include the myenteric plexus should be interpreted with caution.*

See our response to reviewer 1.

*One must also bear in mind that these patients had clinical PD, with abundant α-synuclein inclusions in brain. What one cannot exclude is that the enteric nervous system was affected during the prodrome of PD, but did not have any more α-synuclein inclusions in the clinical phase.*

It is important to note that we did not find any difference in numbers of submucosal neurons between PD patients and controls. This argues against the possibility that the observed lack of functional or immunocytochemical abnormalities in the submucosal plexus of PD patients was due to loss of the most vulnerable and affected submucosal neurons in earlier phases of the disease (Discussion, second paragraph). We cannot entirely rule out the possibility that some submucosal neurons may have been dysfunctional and/or may have contained α-synuclein inclusions in the prodromal phase of PD but functionally recovered and cleared their inclusions later on in the course of the disease. However, this possibility seems extremely unlikely, given the progressive neurodegenerative nature of PD.

*Of course, this study is limited by the fact that the authors only looked at duodenal biopsies. There might have been α-synuclein inclusions elsewhere.*

We agree with this point. We already discussed this limitation in the previous version of the manuscript and included this again in the revised manuscript): 'It is possible that the duodenum was not the optimal site for detection of neuronal changes in PD. \[...\] Also, duodenal endoscopy is generally better tolerated and requires less demanding patient preparation compared to colonoscopy.'

*Is it possible that there were some in the duodenum as well, but that they were missed during gastroduodenoscopy?*

Indeed, we cannot exclude the possibility that the duodenal submucosal plexus in PD patients may be affected in a 'patchy' fashion and that we missed affected ganglia due to sampling error. To acknowledge this, we have added the following sentence to the Discussion: "Finally, we cannot exclude the possibility that the duodenal submucosal plexus in PD patients is affected in a non-uniform, 'patchy' fashion and that we missed affected ganglia due to spatial sampling error."

*Reviewer \#3:*

*The manuscript by Desmet et al. describes an important set of experiments examining the properties of live, human submucosal neurons taken from Parkinson\'s disease (PD) patients and spousal controls. These studies found no differences between PD submucosal neurons and controls in several assays, including apparent viability, neuronal density, cytosolic Ca^2+^ influx in response to depolarization, mitochondrial membrane potential, mitochondrial density or α-synuclein immunoreactivity. Given the widespread belief that PD originates in the GI tract and initially manifest as submucosal pathology, the results of this study, even though they are negative, are very important. From a technical standpoint, the studies are very nicely done and clearly illustrated. The manuscript is well-written (although the Discussion should be shortened), circumspect (e.g., the limitations of the study are clearly stated) and scholarly. I have only a few concerns.*

*• The TMRE measurements should be calibrated by using oligomycin and FCCP to hyperpolarize and depolarize mitochondria.*

We agree that the fluorescence generated by TMRE needs to be interpreted with caution and that is indeed important to pharmacologically check whether the labeling is targeted specifically to mitochondria. To this end we used, as suggested, FCCP to fully depolarize mitochondria. We found that there was a complete destaining, which indeed indicates that our loading paradigm specifically labeled mitochondria. We included this in the Materials and methods section and added a figure of a destaining experiment as a supplementary figure in the revised manuscript [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

Due to the complex nature of the biopsy preparations, we were not able to fully calibrate the TMRE signals using consecutive additions of oligomycin and FCCP. The main reason is that our loading protocol differed substantially from what is used in monolayer cell cultures. Instead of loading TMRE uniformly during tens of minutes, we chose to topically inject TMRE in the sparse neuronal structures present in the biopsy. In this way, we avoided labeling of mitochondria in other than submucous ganglionic structures. For the same reason, we did not add a low concentration of TMRE in the recording buffer as needed for calibration (references 7, 8 below). This decision precluded TMRE calibration in our preparations as one of the necessary steps for calibration is to hyperpolarize the mitochondria using oligomycin. In the absence of TMRE in the surrounding buffer, hyperpolarization would not cause uptake of extra dye. Even though in this study we are not able to derive absolute mitochondrial membrane potentials (in mV) from the TMRE fluorescence, we are convinced that the signals correctly reflect the mitochondrial potentials in the two groups and that our comparison between PD patients and control subjects is entirely valid.

*Was TMRE at non-quenching concentrations?*

In preliminary experiments, we optimized the injection methodology as well as the TMRE concentration. We found that ± 10 minutes after injection of a local bolus of TMRE (at a relatively high concentration of 300 nM) images with a good signal to noise ratio could be recorded. This loading procedure varies substantially from what is possible in cellular monolayers (7,8), where often the dye (albeit at a lower concentrations) is incubated for several minutes (see also comment related to TMRE calibration). However, even though the TMRE concentration used in the injection pipette is relatively high, we assume that all observations were made in non-quenching TMRE mode, because after the topical injection (\~ 150 nl^\*\*^) the dye rapidly diffuses into a larger volume (dilution by a factor 40 if the volume of biopsy \[6mm³\], or \~3.10^3^ if the 500 µl recording bath volume is considered).

Moreover, image stacks were recorded in submucosal plexus structures away from the injection spot, to assure we recorded at lower concentrations than what was injected. The assumption that the TMRE recordings were made in non-quenching mode is corroborated by the fact that closer to the injection site mitochondria behaved similarly than at a short distance away. Therefore, we are convinced that the signals can be reliably interpreted as a good qualitative assessment of mitochondrial function.

We have expanded the Materials and methods section to describe the loading methodology, including the discussion about dye concentration and diffusion after injection (subsection "Mitochondrial imaging", first paragraph).

^\*\*^ We measured the ejected volume by navigating the pipette tip (n=4) in a drop of oil after which the volume of the drop could be estimated based on the diameter of the sphere (160 ± 47 nl).

*• Using TMRE for the mitochondrial density estimates is a bit problematic because it brings mitochondrial membrane potential into the picture, whereas a mitochondrially targeted GFP or mitotracker green wouldn\'t have done so. I understand the need for a rapid, diffusible marker with the biopsies but the authors should discuss the limitations of this aspect of the study in the main body of the text.*

We agree that this is indeed a good point. In our original experimental design, we planned to use a dual injection of mitotracker green (MTG) and TMRE. However, the MTG dye, unlike TMRE, never diffused from the injection spot at room temperature, which made it impossible to use MTG for determining morphology. The reason why MTG is that sticky in human tissue is not yet clear, but it is possible that higher temperatures (37°C) are needed for the dye to spread uniformly. We had already briefly mentioned this in the original Materials and methods section, but have expanded this in the revised manuscript (subsection "Mitochondrial imaging", third paragraph) and now also refer to this point in the Results section (subsection "Mitochondrial volume and numbers in submucous neurons do not differ between PD patients and controls". Although we agree that the use of TMRE (at RT) for comparison of mitochondrial volume and numbers between PD patients and controls is not ideal, we believe that this pragmatic approach was justified based on the fact that there were no differences in TMRE signaling between the two populations.

The reviewer also mentions the possibility of expressing mitochondrially targeted GFP in the neurons. Unfortunately, this is technically not yet possible in our human enteric biopsies. The main problem is that the biopsies would need to be kept alive for much longer to allow a lentivirus- or AAV-based transduction approach to label mitochondria.

*• Was there any difference in mitochondrial morphology in the PD and control samples?*

As part of the analysis, we also measured ellipticity and sphericity of mitochondria. However, due to the limits of optical resolution, even after deconvolution, it was impossible to reliably determine the morphology of all mitochondria. Clusters of mitochondria were often identified as one, which made it impossible to interpret the values of ellipticity and sphericity. Therefore, we decided not to include these data in the manuscript. An example of this analysis is shown in [Author response image 1](#fig7){ref-type="fig"}.10.7554/eLife.26850.027Author response image 1.Representative TMRE volume detection in the submucosal plexus.The first panel shows the typical volume detection (yellow) with additional spot detection (blue). The second picture is showing a color-coded image specific for sphericity. Within the white dotted line a cluster of mitochondria can be seen even if multiple spots were detected in this volume. Due to resolution limits, this cluster of mitochondria cannot be separated in individual mitochondria, not even after deconvolution. As seen from the color code, sphericity of this cluster is not representative for the sphericity of one mitochondrion. The third and fourth picture represent the same structure, representatively color-coded for ellipticity (oblate) and ellipticity (prolate).**DOI:** [http://dx.doi.org/10.7554/eLife.26850.027](10.7554/eLife.26850.027)

*Reviewer \#4:*

*Desmet et al. investigate enteric neuronal function from duodenal biopsies in patients with Parkinson\'s disease and controls. The goal is to explore whether functional assays can detect evidence consistent with the established increased prevalence of GI symptomatology and predilection for α-synuclein pathology in the enteric nervous system. The experiments do not detect any differences between cases and spouse controls, based on calcium imaging, mitochondrial membrane potential, and assessments of mitochondrial numbers. None of the biopsies had demonstrable α-synuclein aggregate pathology, making it difficult to conclude whether the negative results might be due to sampling issues. While innovative, the negative results in this small cohort, allow only preliminary conclusions to be drawn at this stage. This manuscript is not appropriate for eLife, and would be better suited to a neurology journal.*

Due to the nature of the work, which is at the interface of gastroenterology and neurology, and given the increasing interest in the gut (e.g. microbiome; inflammatory diseases) as a potential source or gateway for several diseases, we believe that this work would be of interest to a wider scientific audience than only clinical neurologists, and would like to defend our choice to submit to *eLife*.

*Suggestions for improving the manuscript:*

*It would be helpful to discuss further whether prior studies have found synuclein pathology with similar frequency in the submucosal vs. myenteric plexus.*

See our response to reviewers 1.

*Consider the possibility that pathology and dysfunction of the ENS may be \"patchy\", complicating interpretation of studies of selective biopsies.*

See our last response to reviewer 2.

*It would be interesting in the Discussion (or Introduction) to discuss any results from PD animal model studies of the GI tract.*

The Thy1-αSyn mouse, which overexpresses human wild-type α-synuclein, has been reported to have abnormal colonic motility (9), but otherwise we are not aware of any publications showing gastrointestinal abnormalities in the currently available genetic mouse models of PD.

Several studies have investigated the GI tract in toxin-based animal models of PD. Rats with a unilateral nigrostriatal lesion induced by intracerebral injection of 6-hydroxydopamine were reported to have a reduction in daily fecal output and a loss of nitrergic enteric neurons in the distal ileum and proximal colon, suggesting that loss of nigrostriatal neurons may induce secondary changes in the enteric nervous system (10). Chronic intragastric administration of low doses of rotenone was reported by Pan-Mantojo et al. to induce α-synuclein aggregates in the enteric nervous system of mice (11), whereas chronic oral administration of rotenone to mice did not induce α-synuclein aggregates but rather a decrease of α-synuclein expression in the enteric nervous system in the study by Tasselli et al. (12). MPTP, a compound that selectively kills nigrostriatal dopaminergic neurons, has been reported to also reduce the number of dopaminergic neurons in the myenteric and submucosal plexuses in mice and monkeys (13-15). However, data from these toxin-based models need to be interpreted with caution, because the relevance of these toxins for the pathogenesis of human PD is still questionable.

We have cited the animal work by Pan-Mantojo et al. in the manuscript, but would prefer not to add an extensive discussion of GI tract studies in PD animal models to the revised manuscript because our study focuses on human tissue and also because reviewers 3 and 4 suggested to shorten the Discussion.

*The discussion could be shortened.*

This was also suggested by reviewer 3. In the revised Discussion we have added several caveats for the interpretation of our data (the limitation of not having access to the myenteric plexus data, and the possibility of 'patchiness' of the pathology in the duodenum), as suggested by the reviewers. Nevertheless, we have managed to shorten the Discussion compared with the previous version (from a total of 1324 words to 1210 words).

*I suggest caution not to overstate the conclusion given the many caveats: \"our findings... strong suggests that GI symptoms in PD do not arise from disturbed sub mucous neuronal function\".*

We carefully screened the paper to tone down the interpretation of the results, mainly by removing words like "strongly" etc. We were careful not to overstate the results and further expanded the list of limitations of our study in the Discussion by adding a statement about the lack of myenteric data (third paragraph) and about the possibility of 'patchiness' and sampling errors (seventh paragraph).

*The authors also overstate the degree of controversy surrounding enteric nervous system pathology in PD (e.g. Introduction, second paragraph). While there is certainly debate about the potential utility as a clinical biomarker and the best staining protocol, I believe most experts agree that the ENS is pathologically involved.*

We agree that most researchers still believe that the ENS is pathologically involved in PD. As suggested by the reviewer, we have been careful not to overstate the degree of controversy surrounding enteric nervous system pathology in PD in the revised manuscript. In the revised Introduction we have replaced the phrase 'Given the current controversy with respect to enteric α-synuclein immunohistochemistry...' by 'Given the current debate about the potential utility of enteric α-synuclein immunohistochemistry as a biomarker for PD...'. In the revised Discussion, we have replaced the sentence 'So far, the outcome of these studies has been variable and controversial' by 'So far, the outcome of these studies has been variable'.
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